Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy

Immune checkpoint inhibitors (ICIs) have activity across many tumor types, but activation of the immune system may also lead to significant, often steroid-refractory immune-related adverse events (irAEs). We sought to determine the activity of tocilizumab, an anti-interleukin-6 receptor monoclonal a...

Full description

Saved in:

Bibliographic Details
Published in:	European journal of cancer (1990) Vol. 157; pp. 214 - 224
Main Authors:	Dimitriou, Florentia, Hogan, Sabrina, Menzies, Alexander M., Dummer, Reinhard, Long, Georgina V.
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 01.11.2021 Elsevier Science Ltd
Subjects:	Adult Adverse events Aged Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Autoimmune diseases Autoimmune Diseases - complications Autoimmune Diseases - diagnosis Autoimmune Diseases - immunology Autoimmune Diseases - prevention & control C-reactive protein C-Reactive Protein - analysis Cancer Cancer immunotherapy Clinical trials Cytokines Drug-Related Side Effects and Adverse Reactions - blood Drug-Related Side Effects and Adverse Reactions - diagnosis Drug-Related Side Effects and Adverse Reactions - drug therapy Drug-Related Side Effects and Adverse Reactions - immunology Evaluation Female Humans Immune checkpoint inhibitors Immune Checkpoint Inhibitors - adverse effects Immune system Immune-related adverse events Immunotherapy Inflammatory reaction Interleukin 6 Interleukin-6 - antagonists & inhibitors Male Melanoma Melanoma - complications Melanoma - drug therapy Melanoma - immunology Middle Aged Monoclonal antibodies Patients Prevention Prophylaxis Prospective Studies Retrospective Studies Skin Neoplasms - complications Skin Neoplasms - drug therapy Skin Neoplasms - immunology Steroids Survival Symptom Flare Up Tocilizumab Toxicity Tumors Immune-related adverse events Tocilizumab Inflammatory reaction Immunotherapy
ISSN:	0959-8049, 1879-0852, 1879-0852
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!